Stéphane Pillet

TL;DR: The present work shows that a combination of three neutralizing monoclonal antibodies directed against the Ebola envelope glycoprotein (GP) resulted in complete survival (four of four cynomolgus macaques) with no apparent side effects when three doses were administered 3 days apart beginning at 24 hours after a lethal challenge with EBOV.

TL;DR: The authors detected specific antibody responses to ZEBOV that correlate with survival in multiple animal models (mouse, guinea pig, and nonhuman primates) and suggest these immune responses may be used as surrogates for testing a successful vaccine.

TL;DR: The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with E BOV, which resulted in sustained protection against a second lethal exposure.

TL;DR: It is shown that airway vaccination with adenovirus serotype 5-based Ebola virus vaccine can efficiently bypass preexisting immunity to adenvirus serotypes 5 and induce protective immune responses, albeit at lower efficacy than that using an intramuscular vaccine delivery route.

TL;DR: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.